Zapomeran

DB21761ApprovedVaccines

Zapomeran is a COVID-19 vaccine composed of self-amplifying mRNA encoding the spike protein of SARS-CoV-2 encapsulated in lipid nanoparticles. Zapomeran, marketed under the brand name Kostaive (ARCT-154), is a self-amplifying mRNA COVID-19 vaccine for individuals 18 years and older.

Mechanism: Zapomeran is composed of a self-amplifying mRNA encoding the spike protein of SARS-CoV-2, encapsulated in lipid nanoparticles. The self-amplifying mRNA is designed to produce extra copies of mRNA within the host cells after intramuscular injection in order to achieve enhanced expression of the spike protein antigen. This gives rise to neutralizing antibody and cellular immune responses to the spike antigen, ultimately contributing to protection against COVID-19. The mRNA self-amplification process is transient and does not generate infectious particles.
Curator reviewed · 1 reference
Primary indication: In the European Union, zapomeran is indicated for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 18 years of age and older.Curator reviewed · 1 structured indication
First approval: European Union, 2025
Code names: ARCT-154 · mRNA-2105

Resolves to

Compound

UNIIJ9E7RSF8K3CAS2727965-96-8

What you can answer from here — as of July 08, 2025

2Clinical trialsPhase, status and sponsor resolved per trial

1Structured indicationCondition, population, route and combination as fields, not prose

1ContraindicationEach with its own population and attribute set

1Marketed productAcross 1 country and 1 labeller

4+ReferencesStructured and connected to the statements they support

Which other approved drugs treat the same conditions as Zapomeran, and which companies have late-stage candidates in those indications?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account